Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: Focus on drug-drug interactions with rifamycins

Clinical Pharmacokinetics

Volumn 53, Issue 6, 2014, Pages 489-507

  Regazzi, Mario ^a   Carvalho, Anna Cristina ^b,c   Villani, Paola ^a   Matteelli, Alberto ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ENZYME INHIBITOR; RIFAMYCIN; TUBERCULOSTATIC AGENT;

CD4 LYMPHOCYTE COUNT; CHILDHOOD DISEASE; CLINICAL RESEARCH; CONCURRENT INFECTION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POPULATION GROUP; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUBERCULOSIS; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; ENZYME INDUCTION; HIV INFECTIONS; ISOLATION AND PURIFICATION;

ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RIFAMYCINS; TUBERCULOSIS;

EID: 84903744433     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0144-3     Document Type: Review

References (130)

1. World Health Organization (WHO). Global tuberculosis report 2013. WHO/HTM/TB/2013.11. http://apps.who.int/iris/bitstream/10665/91355/1/ 9789241564656-eng.pdf. Accessed 3 Jan 2014.
2. UNAIDS. UNAIDS report on the global AIDS epidemic 2013. UNAIDS/JC2502/1/E. http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 3 Jan 2014.
3. World Health Organization (WHO). Treatment of tuberculosis guidelines. Fourth edition. 2010. http://whqlibdoc.who.int/publications/2010/9789241547833- eng.pdf. Accessed 3 Jan 2014.
4. International Standards for Tuberculosis Care (ISTC), 2nd ed. The Hague: Tuberculosis Coalition for Technical Assistance; 2009. http://www.currytbcenter. ucsf.edu/international/istc-report-2nded.pdf. Accessed 3 Jan 2014.
5. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 3 Jan 2014.
6. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection - recommendations for a public health approach. http://apps.who.int/iris/bitstream/10665/85321/1/ 9789241505727-eng.pdf. Accessed 3 Jan 2014.
7. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. doi:10.1371/journal.pmed.1001270.
8. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource limited settings. Clin Chest Med. 2009;30:685-99.
9. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.
10. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-81.
11. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-91.
12. Abdool Karim SN, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492-501.
13. Arentz M, Pavlinac P, Kimerling ME, Horne DJ, Falzon D, Schünemann HJ, et al. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One. 2012;7:e47370. doi:10.1371/journal.pone.0047370.
14. World Health Organization (WHO). WHO policy on collaborative TB/HIV activities. Guidelines for national programmes and other stakeholders. http://whqlibdoc.who.int/publications/2012/9789241503006-eng.pdf. Accessed 3 Jan 2014.
15. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196(Suppl 1):S63-75. (Pubitemid 47206086)
16. Gengiah TN, Gray AL, Naidoo K, Karim QA. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf. 2011;10:559-74.
17. Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis. 2012;55:1154-63.
18. Nunn AJ, Jindani A, Enarson DA, Study A investigators. Results at 30 months of a randomized trial of two 8-month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011;15:741-5.
19. Matteelli A, Richardson MD, Sotgiu G, Centis R, Migliori GB. Multidrug- and extensively drug-resistant TB in persons living with HIV. Exp Rev Respir Med. 2009;3:245-54.
20. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page- Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-807.
21. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-28.
22. da Silva PA, Aínsa JA. Drugs and drug interactions. Chapter 18. In: Palomino JC, Cardoso Leão S, Ritacco V. Tuberculosis 2007-from basic science to patient care. pp. 593-634. http://www.TuberculosisTextbook.com. Accessed 3 Jan 2014.
23. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations - part 1: first-line drugs. J Bras Pneumol. 2010;36:626-40.
24. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126-36. (Pubitemid 351253409)
25. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819-50. (Pubitemid 36995083)
26. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampicin is a selective, pleiotropic inducer of drug metabolism: studies with cDNA and oligonucleotide expression assays. J Pharmacol Exp Ther. 2001;299:849-57. (Pubitemid 33104951)
27. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013;57:6366-9.
28. Magnusson MO. Pharmacodynamics of enzyme induction and its consequences for substrate elimination [thesis]. Uppsala: Uppsala Universitet; 2007. Distribution: publications.uu.seurn: nbn:se:uu:diva-7812.
29. Magnusson MO, Karlsson MO, Sandström R. A mechanism based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. Pharm Res. 2006;23:521-32.
30. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852-6.
31. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147-53.
32. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996;22(Suppl):S15-22. (Pubitemid 26256453)
33. Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N, Koudriakova T. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther. 1997;61(5):554-62. (Pubitemid 27261759)
34. Keung ACF, Owens RC Jr, Eller MG, Weir SJ, Nicolau DP, Nightingale CH. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Antimicrob Agents Chemother. 1999;43(5):1230.
35. Rastogi N, Goh KS, Berchel M, Bryskier AJ. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. Antimicrob Chemother. 2000;46(4):565-70.
36. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327-41. (Pubitemid 32565595)
37. Rifapentine - a long-acting rifamycin for tuberculosis. Med Lett Drugs Ther 1999;41:21-2.
38. Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis. 2006;43:1468-1475. (Pubitemid 44845652)
39. Keung A, Reith K, Eller MG, McKenzie KA, Cheng L, Weir SJ. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Int J Tuberc Lung Dis. 1999;3:426-36. (Pubitemid 29294694)
40. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978;3:108-27.
41. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360:528-34.
42. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis trials consortium. Lancet. 1999;353:1843-7. (Pubitemid 29251017)
43. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167:1341-7. (Pubitemid 36609717)
44. Centers for Disease Control. Managing drug interactions in the treatment of HIV-related tuberculosis. http://www.cdc.gov/tb/publications/guidelines/TB- HIV-Drugs/pdf/tbhiv.pdf. Accessed 3 Jan 2014.
45. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2004;37(Suppl 1):S2-12.
46. Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol. 1999;48:168-79. (Pubitemid 29349452)
47. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5. (Pubitemid 32055781)
48. Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. 2009;14:687-95.
49. Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug - drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob Agents Chemother. 2013;57:1019-24.
50. Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther. 2010;7:8.
51. Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648-53.
52. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58:1299-302. (Pubitemid 44884158)
53. López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681-90.
54. Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC, et al. Multiple dose pharmacokinetics of efevirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res. 2007;5:349-53. (Pubitemid 46785071)
55. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virusinfected patients in South India. Antimicrob Agents Chemother. 2009;53:863-8.
56. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine- and efavirenzbased antiretroviral therapy when coadministered with rifampi-cin-based antitubercular therapy. JAMA. 2008;300:530-9.
57. Matteelli A, Carvalho AC, Apostoli A, Tinelli C, Scudeller L, El Hamad I et al. Completion rate and viro-immunological response to combined TB/HIV treatment: results from the RIFART study [abstract no. 854]. 20th Conference on Retroviruses and Opportunistic Infections; 3-6 Mar 2013; Atlanta.
58. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS. 2011;25:388-90.
59. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20:131-2. (Pubitemid 41818129)
60. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocaña I, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28:450-3. (Pubitemid 34033196)
61. Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61:389-93.
62. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2005;10:937-43. (Pubitemid 43076345)
63. Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol. 2009;65:71-80.
64. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, N2R Study Team, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reversetranscriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009;48:1752-9.
65. Matteelli A, Saleri N, Villani P, Bonkoungou V, Carvalho AC, Kouanda S, et al. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. J Acquir Immune Defic Syndr. 2009;52:64-9.
66. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther. 2007;12:515-21. (Pubitemid 47041150)
67. Moses M, Zachariah R, Tayler-Smith K, Misinde D, Foncha C, Manzi M, et al. Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. Int J Tuberc Lung Dis. 2010;14:197-202.
68. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13:529-36. (Pubitemid 352016715)
69. Manosuthi W, Tantanathip P, Chimsuntorn S, Eampokarap B, Thongyen S, Nilkamhang S, Sungkanuparph S. Treatment outcome of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. Int J Infect Dis. 2010;14:1013-7.
70. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53:716-24.
71. Sinha S, Raghunandan P, Chandrashekhar R, Sharma S, Kumar S, Dhooria S et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. BMC Infect Dis 2013;13:482. http://www.biomedcentral.com/1471-2334/ 13/482.
72. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis. 2013;13:303-12.
73. Benedek IH, Fiske WD, White SJ, Stevenson J, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between multiple doses of efavirenz (EFV) and rifabutin in healthy volunteers [abstract no. 461]. In: Program and abstracts of the Infectious Diseases Society; 12-15 Nov 1998; Denver.
74. Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis. 2005;41:1343-9. (Pubitemid 41532682)
75. Maldonado S, Lamson M, Gigliotti M, et al. Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifabutin (RFB) [abstract no. 341]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 26-29 Sep 1999; San Francisco.
76. Van Heeswijk R, Hoetelmans RMW, Kestens D, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) [abstract no. 74]. 7th International Workshop of Clinical Pharmacology; 20-22 Apr 2006; Lisbon.
77. Crauwels H, van Heeswijk R, Kestens D, et al. The pharmacokinetic (PK) interaction between rifabutin and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) [abstract no. TUPE0080]. 17th International AIDS Conference; 3-8 Aug 2008; Mexico City.
78. Crauwels H, van Heeswijk RP, Stevens M, Buelens A, Vanveggel S, Boven K, Hoetelmans R. Clinical perspective on drug - drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87-101.
79. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50:25-39.
80. Kakuda TN, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F, Hoetelmans RM. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. J Antimicrob Chemother. 2014;69(3):728-34. doi:10.1093/jac/dkt421.
81. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther. 1997;61:544-53. (Pubitemid 27261758)
82. Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res. 1997;35:53-63. (Pubitemid 27261206)
83. Centers for Disease Control and Prevention (CDC). Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep. 1996;45:921-5.
84. Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3336-42. (Pubitemid 44527507)
85. Goutelle S, Baudry T, Gagnieu MC, Boibieux A, Livrozet JM, Peyramond D, et al. Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients. Antimicrob Agents Chemother. 2013;57(1):517-23.
86. la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, et al. Pharmacokinetics of adjusted-dose lopinavirritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:1553-60. (Pubitemid 38544359)
87. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G. Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets. Antimicrob Agents Chemother. 2011;55:3195-200.
88. Grange SM, Schutz C, Schmitt M, Gaudeul-Ehrhart R. Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted sequinavir and vice versa [abstract no. 35]. 6th International Workshop on Clinical Pharmacology and HIV Therapy; 28-30 Apr 2005; Montreal.
89. Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009;50:290-3.
90. Nijland HM, L'homme RF, Rongen GA, van Uden P, van Crevel R, Boeree MJ, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008;22:931-5.
91. Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron E. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PloS One. 2012;7:e32173. doi:10.1371/journal.pone.0032173.
92. Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS One. 2012;7:e44793. doi:10.1371/journal.pone.0044793.
93. Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud- Thery F, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis. 2012;16:6-15.
94. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007;(4):CD005159.
95. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis. 1994;75:341-7. (Pubitemid 24336530)
96. McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154:1462-7. (Pubitemid 26391198)
97. Matteelli A, Villani P, Carvalho AC, El-Hamad I, Cusato M, Apostoli A, et al. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother. 2012;67:2470-3.
98. Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. MMWR Recomm Rep. 2004;53(15):1-112.
99. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49:1305-11.
100. Khachi H, O'Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Anti-microb Chemother. 2009;64:871-3.
101. Tanuma J, Sano K, Teruya K, Watanabe K, Aoki T, Honda H, et al. Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy. PLoS One. 2013;8:e70611. doi:10.1371/journal.pone. 0070611.
102. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40:1481-91. (Pubitemid 40628637)
103. Jenny-Avital E, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009;48:1471-4.
104. Lan NT, Thu NT, Barrail-Tran A, Duc N, Lan NN, Laureillard D, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir- antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014;9(1):e84866. doi:10.1371/journal.pone.0084866.
105. Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother. 2011;66:2075-82.
106. Ramachandran G, Bhavani PK, Hemanth Kumar AK, Srinivasan R, Raja K, Sudha V, et al. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. Int J Tuberc Lung Dis. 2013;17:1564-8.
107. Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54:4440-5.
108. Ford SL, Chen YC, Lou Y, Borland J, Min S, Yuen GJ, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother. 2008;52:534-8. (Pubitemid 351170825)
109. la Porte CJL, Sabo JP, Elgadi M, Cameron DW. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. Antimicrob Agents Chemother. 2009;53:162-73.
110. Burger DM, Magis-Escurra C, van den Berk GE, Gelinck LB. Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS. 2010;24:328-30.
111. Mena A, Vázquez P, Castro Á, López S, Bello L, Pedreira JD. Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis. J Antimicrob Chemother. 2011;66:951-2.
112. French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS). Efficacy and safety of 2 raltegravir doses in naive HIV-1-infected patients receiving rifampin for active tuberculosis. http://clinicaltrials.gov/show/NCT00822315 Accessed 3 Jan 2014.
113. Grinsztejn B, De Castro N, Arnold V, et al. A randomized multicentre open-label trial to estimate the efficacy and safety of two doses of raltegravir (RAL) to efavirenz (EFV) for the treatment of HIV-TB co-infected patients: results of the ANRS 12 180 Reflate TB trial [abstract no. THLBB01]. In: Program and Abstracts of the XIX International AIDS Conference; 22-27 Jul 2012; Washington, DC.
114. Brainard DM, Kassahun K, Wenning LA, Pety AS, Liu C, Lunceford J, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol. 2011;51:943-50.
115. Lee JS, Calmy A, Andrieux-Meyer I, Ford N. Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV AIDS. 2012;4:5-15.
116. German P, West S, Hui J, Kearney BP. Pharmacokinetic inter-action between elvitegravir/ritonavir and dose-adjusted rifabutin [abstract no. P19]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 Apr 2008; New Orleans.
117. Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-EFV with atazanavir, rosuvastatin or rifabutin [abstract no. O-03]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 Apr 2012; Barcelona.
118. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21-7.
119. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos. 2005;33:587-95. (Pubitemid 40393203)
120. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl. 1):38-46. (Pubitemid 351366537)
121. Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44:175-86. (Pubitemid 40188939)
122. Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol. 2003;43:1382-91. (Pubitemid 37433312)
123. Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 2012;35:113-59.
124. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-61. (Pubitemid 38917251)
125. Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010;11:334-44.
126. Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis. 2010;201:106-13.
127. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with
128. Elsherbiny D, Ren Y, McIlleron H, Maartens G, Simonsson US. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol. 2010;66:1017-23.
129. Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, Meyers T. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011;6:e17273. doi:10.1371/journal.pone.0017273.
130. Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART. AIDS. 2011;25:49-55.